Latest Content

Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD, discusses recent CLL approvals, BTK and BCL-2 inhibitor safety, and individualizing frontline therapy.

The top 5 OncLive TV videos of the week cover insights in NSCLC, large granular lymphocytic leukemia, ovarian cancer, and myelofibrosis.

Long-term data from the L-MOCA trial showed encouraging OS outcomes with olaparib maintenance in Asian patients with platinum-sensitive, relapsed ovarian cancer.

The FDA approved imlunestrant plus abemaciclib in breast cancer and photodynamic therapy in skin cancer, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The phase 3 REZILIENT3 trial met its primary end point at a pre-specified interim analysis, with a median PFS of 14.5 months and a 65.0% ORR.

CHMP has recommended EU approval of senaparib for advanced ovarian cancer based on FLAMES data.

The CHMP recommended perioperative pembrolizumab plus enfortumab vedotin for resectable muscle-invasive bladder cancer.

The FDA approved imlunestrant/abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after progression on endocrine therapy.

The CHMP recommended approval of adjuvant T-DXd for HER2-positive early breast cancer with residual invasive disease after neoadjuvant therapy.

Udai S. Kammula, MD, FACS, discusses TIL therapy outcomes, the UMIS biomarker, and treatment implications in metastatic uveal melanoma.

CHMP has recommended EU marketing authorization for relacorilant combined with nab-paclitaxel in platinum-resistant ovarian cancer.

The positive CHMP opinion for teclistamab in second- and later-line relapsed/refractory multiple myeloma is supported by MajesTEC-9 data.

CHMP offerred a positive opinion supporting extension of melflufen to third-line, lenalidomide-refractory multiple myeloma.

Brandon Huffman, MD, discusses INCB161734’s mechanism of action, phase 1 data, and the DAWN-303 trial design in KRAS G12D–mutated pancreatic cancer.

Mayo Clinic researchers reported data for minibeam radiotherapy for treatment-resistant cancers in or near the skin.

Mosunetuzumab plus lenalidomide met the CELESTIMO trial's primary end point, improving PFS in relapsed/refractory follicular lymphoma.

The latest updates to the NCCN Guidelines for multiple myeloma expand minimal residual disease testing guidance.

The FDA has cleared an sNDA updating the taletrectinib (Ibtrozi) label with new DOR data in TKI-naive patients with locally advanced or metastatic ROS1-positive NSCLC.

A marketing authorization application for lirafugratinib in previously treated FGFR2-altered metastatic cholangiocarcinoma has been submitted to the EMA.

Toon Van Gorp, MD, PhD, discusses NAPISTAR 1-01 trial design, safety findings, and efficacy across dose levels of TUB-040 in ovarian cancer.

A PET-guided, nivolumab-based regimen produced promising response rates in advanced-stage classical Hodgkin lymphoma.

Japan approved T-DXd plus pertuzumab for HER2-positive disease and Dato-DXd for triple-negative disease in first-line metastatic breast cancer.

The University of Texas MD Anderson Cancer Center and Springer Nature will co-host a conference to explore the latest research on cancer therapeutics.

Cesalatamig earned FDA fast track designation for NSCLC that progressed after immunotherapy and platinum-based chemotherapy.

Data from a retrospective study showed high levels of CEACAM1 expression in patients with mantle cell lymphoma.

The phase 2 AMIGO-1 trial met its end point, with an 18-month PFS rate of 66.7% for first-line amivantamab, lazertinib, and pemetrexed in EGFR-mutant NSCLC.

First-line osimertinib plus gefitinib produced an 82.1% response rate and blocked second-site EGFR resistance mutations, but missed feasibility criteria.

Bexobrutideg produced responses across lines of therapy in chronic lymphocytic leukemia/small lymphocytic lymphoma.

The FDA set a target action date of June 29, 2027, for bezuclastinib's NDA in advanced systemic mastocytosis, backed by APEX trial data.

The phase 3 ECHO trial confirmed a durable progression-free survival benefit with frontline acalabrutinib-based therapy in mantle cell lymphoma.

Obesity may increase breast cancer risk partly by removing a natural defense.

Daraxonrasib plus gemcitabine and nab-paclitaxel received FDA breakthrough therapy designation for treatment-naive metastatic pancreatic adenocarcinoma.

KST-6051 received FDA fast track designation for KRAS-mutant solid tumors.

Alexandra Leary, MD, PhD, discusses TEDOVA's design, the safety profile of OSE2101, and implications for maintenance in ovarian cancer.

ASCO's first living guideline backs platinum doublets and mirvetuximab soravtansine for FRα+, high-grade platinum-resistant ovarian cancer.

Osimertinib plus platinum-pemetrexed showed a numerical PFS and OS advantage over osimertinib alone regardless of baseline TP53 status in FLAURA2.

The FDA has approved lutetium Lu 177 dotatate injection for SSTR-positive GEP-NETs, including foregut, midgut, and hindgut NETs.

Strong overall response rates with pirtobrutinib in relapsed/refractory CLL previously treated with covalent BTK inhibitors were shown in a pooled analysis.

Real-world tumor lysis syndrome occurred in less patients with CLL who received venetoclax-based regimens than those with MCL.

Dana-Farber Cancer Institute is launching Solavia Decision Suite to bring clinical expertise and evidence-based treatment pathways directly into clinicians’ workflows.

The FDA indication for adagrasib plus cetuximab for KRAS G12C–mutated locally advanced or metastatic colorectal cancer has been removed.

The updated tarlatamab label reduces post-infusion monitoring after each of the first two doses to 6 to 8 hours, down from 22 to 24 hours.